Research programme: melanocortin-4 receptor agonists - Novo Nordisk
Alternative Names: Melanocortin-4 receptor agonists research programme - Novo Nordisk; NNC 70-619; Obesity therapy research programme - Novo NordiskLatest Information Update: 16 Jul 2016
At a glance
- Originator Novo Nordisk
 - Class Piperazines; Small molecules
 - Mechanism of Action Melanocortin type 4 receptor agonists
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 
Highest Development Phases
- No development reported Obesity
 
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in Denmark
 - 08 Dec 2004 Data presented at the Annual Scientific Meeting of the North American Association for the Study of Obesity (NAASO-2004) have been added to the adverse events and Obesity pharmacodynamics sections
 - 07 Sep 2004 Preclinical trials in Obesity in Denmark (unspecified route)